The batch record may not tell the whole story
Imagine that a pharmaceutical company has manufactured a batch of tablets.
The Batch Manufacturing Record is complete.
The Batch Packaging Record is complete.
QC results are within specification.
The QA review is satisfactory.
The batch is released.
At first glance, everything appears normal.
But what if someone asks a much more difficult question?
“Can you prove exactly what happened during the manufacture and testing of this batch?”
That question changes the investigation completely.
A pharmaceutical batch does not generate only a BMR or BPR. During its journey through a manufacturing facility, it can generate hundreds or thousands of pieces of information.
Some are on paper.
Some are electronic.
Some are stored in laboratory systems.
Some are stored in ERP or manufacturing systems.
Some exist in equipment records.
Some exist in audit trails.
Some may even exist in access-control or environmental monitoring systems.
Together, these records can create what we can describe as the:
“Digital Shadow” of a Pharmaceutical Batch
The term “digital shadow” is useful for understanding the interconnected information surrounding a batch. It is not a regulatory term by itself.
The important regulatory concept is data integrity.
FDA states that data used to support CGMP decisions must be reliable and accurate and recommends risk-based strategies for preventing and detecting data-integrity problems.
WHO guidance similarly emphasizes audit trails and the ability to reconstruct relevant GxP activities through reliable electronic records and metadata.
What exactly is the digital shadow of a batch?
Consider a typical pharmaceutical batch.
It may pass through:
Raw Material Receipt
↓
Sampling
↓
QC Testing
↓
Dispensing
↓
Manufacturing
↓
In-Process Testing
↓
Bulk Storage
↓
Packaging
↓
Finished Product Testing
↓
QA Review
↓
Batch Release
↓
Warehouse
↓
Distribution
At almost every stage, information is created.
For example:
| Area | Examples of information generated |
|---|---|
| Warehouse | Receipt, quantity, material status, movement |
| QC | Sampling, testing, results, raw data |
| Dispensing | Weighing, operator, material quantity |
| Production | Process parameters, equipment usage |
| IPQA | Line clearance, IPC, observations |
| Engineering | Calibration, maintenance, breakdown |
| HVAC | Temperature, RH, differential pressure |
| LIMS | Sample registration, results, approvals |
| HPLC/GC/UV | Raw analytical data and metadata |
| ERP/SAP | Material and inventory transactions |
| MES | Electronic manufacturing information |
| BMS/SCADA | Environmental/process information |
| Access Control | Entry/exit records |
| DMS | Controlled documents and approvals |
| Backup systems | Preservation and recovery of electronic information |
| QA | Deviations, OOS, CAPA, change controls |
The BMR is therefore only one part of the evidence surrounding a batch.
Why this matters during a regulatory inspection
An inspector may not simply ask:
“Show me the BMR.”
The investigation may go much further.
For example:
Who performed the activity?
When was it actually performed?
Which equipment was used?
Was the equipment available and released for use?
Was it calibrated?
Was cleaning completed?
What happened in the laboratory?
Were there repeated injections?
Were electronic records modified?
Was the audit trail reviewed?
Were original data retained?
Who approved the result?
Can the company reconstruct the sequence of events?
This is why modern pharmaceutical data integrity is not simply about keeping documents safely.
It is about maintaining trustworthy evidence throughout the data lifecycle.
A pharmaceutical batch leaves many fingerprints
A useful way of thinking about a batch is to imagine that every important activity leaves a fingerprint.
For example:
BMR fingerprint
What was documented?
Equipment fingerprint
Which equipment was used and when?
Laboratory fingerprint
What analytical data were generated?
Audit-trail fingerprint
What was created, changed or deleted?
ERP fingerprint
What material transactions occurred?
Access-control fingerprint
Who entered the relevant area?
Environmental fingerprint
What were the relevant environmental conditions?
QA fingerprint
What deviations, investigations and approvals occurred?
None of these records should automatically be assumed to be infallible.
But together, appropriately controlled records can help investigators understand what actually happened.
The first question: Who actually performed the activity?
Suppose a BMR contains an entry stating:
“Granulation completed at 14:30.”
The document contains an operator signature.
Is that enough?
Not necessarily.
Depending on the activity and systems involved, an investigation may also consider:
operator authorization
training status
electronic user account
equipment login
access-control record
electronic batch record
equipment activity
contemporaneous observations
related documentation
This does not mean that access-control records automatically prove who performed a GMP activity.
They are simply another potentially relevant piece of evidence.
A discrepancy should trigger investigation—not an automatic conclusion.
The second question: Was the equipment actually available?
Imagine that a BMR states:
Equipment XYZ-101 used from 09:00 to 11:00.
The investigator may want to understand:
Was XYZ-101 available?
Was it cleaned?
Was cleaning verified?
Was it calibrated?
Was maintenance ongoing?
Was another batch using the equipment?
Was the equipment released?
Does its electronic record show activity during the same period?
This is where cross-system review becomes powerful.
A record may look correct when viewed alone.
It may look very different when compared with other relevant records.
The third question: What happened inside the laboratory?
Laboratory data are particularly important because a final result may represent only the end product of a much larger data set.
Consider an HPLC analysis.
The final report might show:
Assay: 99.2% — Complies
But the underlying analytical record may include:
Sample identification
Sequence
Injection information
Chromatographic data
Method
Processing method
System suitability
Integration parameters
Reprocessing
User information
Date/time information
Audit trail
Electronic approval
Therefore:
The final printed report is not necessarily the complete analytical story.
FDA specifically addresses audit trails, access controls, original electronic records and laboratory chromatography data in its data-integrity guidance.
The HPLC example that every QA and QC professional should understand
Imagine an analyst performs an HPLC test.
The first processing produces:
Result: 96.8%
The analyst then reprocesses the chromatogram.
The final report shows:
Result: 98.4%
Now the question is not simply:
“Why did the result change?”
The investigation should ask:
Why was the data reprocessed?
Who performed the reprocessing?
What processing parameter changed?
Was the change scientifically justified?
Was the original data retained?
Is the audit trail available?
Was the reprocessing authorized?
Was the reason documented?
Was the final result independently reviewed?
Does the final conclusion remain scientifically valid?
Reprocessing itself is not automatically evidence of wrongdoing.
The critical issue is whether the activity is controlled, attributable, scientifically justified and traceable.
The fourth question: What was happening inside the manufacturing area?
Suppose the BMR records:
Granulation temperature: 55°C
That may be a legitimate recorded process value.
But suppose the manufacturing process is also monitored electronically.
The electronic system may contain:
55°C → 56°C → 58°C → 61°C → 59°C → 55°C
Now the investigator can ask:
How long was the temperature outside the target?
Was an alarm generated?
Was an intervention performed?
Was the excursion documented?
Was the event assessed?
Did it affect product quality?
Was a deviation raised?
The objective is not to make electronic data “win” over the BMR.
The objective is to understand the complete event.
The fifth question: What does the access-control system tell us?
This is one of the most interesting areas of modern pharmaceutical investigations.
Imagine that a critical manufacturing activity is documented at:
02:15 AM
But the relevant operator's access-control record shows entry at:
02:42 AM
Should the company immediately conclude that the BMR was falsified?
No.
There may be several legitimate explanations:
Different access point
System-clock difference
Delayed documentation
Preparation performed earlier
Another authorized person performed part of the activity
Access-control configuration
Emergency access
System malfunction
Documentation error
The discrepancy should therefore be investigated.
A discrepancy is an investigation trigger—not an automatic conclusion.
The sixth question: What happened to the original data?
This is one of the most important questions in data integrity.
Consider:
Original data → Processing → Review → Approval → Final report
If the original data are not retained, the investigator may have difficulty establishing what happened.
Indian regulatory material defines raw data broadly and includes laboratory records, software, computer printouts, spectral charts and automated-equipment data among the types of information that may constitute raw data. It also requires preservation of original entries and audit trails for automated systems.
Therefore, a pharmaceutical company's data-management strategy must consider more than simply saving a PDF report.
“The report” is not always “the data”
This distinction deserves special attention.
Imagine a computerized analytical system.
The company retains:
Final PDF report
But the original electronic data, metadata and relevant audit-trail information are not adequately retained or accessible.
The PDF may show the final result.
But it may not provide the same ability to reconstruct:
what happened before the final result,
what processing occurred,
whether changes were made,
who made them,
when they were made,
why they were made.
That is why original electronic records and appropriate metadata can be critical.
The audit trail: a window into the history of electronic data
An audit trail can record relevant actions affecting electronic records.
Depending on system design, it may help establish:
Who
What
When
Where applicable, why
For example:
User A created a record at 09:12.
User A modified a parameter at 09:18.
User B reviewed the record at 10:02.
User C approved the record at 11:15.
The exact information captured depends on the system and configuration.
WHO's current data-integrity guidance states that relevant GxP audit trails should be enabled and remain enabled, with periodic verification that they remain active throughout the data lifecycle.
The audit trail should not be treated as an IT-only issue
This is an important organizational point.
Audit trails are sometimes treated as something belonging exclusively to:
IT / CSV / Computerized Systems Validation
That is incomplete.
An audit trail may contain information directly relevant to:
QC
QA
Production
Engineering
Regulatory Affairs
Data Integrity
Laboratory Management
The business owner of the system and the quality function have important roles in determining which audit-trail information is relevant and how it should be reviewed.
WHO material also emphasizes risk-based review of relevant audit-trail information rather than indiscriminate review of every system activity.
When two systems tell different stories
Here is a fictional example.
| Record | Time |
|---|---|
| BMR | 08:00 |
| Equipment record | 08:14 |
| Access control | 08:19 |
| LIMS | 08:23 |
| IPC record | 08:05 |
| Electronic batch record | 08:16 |
Which one is correct?
The answer should not be selected simply because one system appears more sophisticated.
The investigation should first understand:
How each timestamp is generated
Whether system clocks are synchronized
Whether time zones or daylight-saving settings apply
Whether entries are contemporaneous
Whether records are manually entered
Whether automatic records are generated at a different process stage
Whether there was a system configuration issue
Whether a deviation exists
Whether product quality was affected
Only after understanding the data-generating processes can the discrepancy be properly assessed.
A fictional GMP investigation: The batch that looked perfect
Let's consider a hypothetical batch.
Product
ABC-500 Tablets
Batch
ABC260915
Manufacturing date
15 September 2026
The batch was manufactured.
QC results passed.
QA reviewed the documentation.
The batch was released.
Nothing appeared unusual.
Later, an investigation was initiated because of an unrelated quality complaint.
The investigation team decided to review the complete batch history.
Finding 1 — BMR
Compression started:
14:00
Finding 2 — Equipment record
Machine activity began:
14:37
Finding 3 — Access control
Operator entered the area:
14:31
Finding 4 — IPC record
First IPC sample:
14:10
Finding 5 — Electronic process record
First relevant electronic record:
14:38
Now there is a question:
What actually happened between 14:00 and 14:38?
The investigation team should not immediately accuse anyone.
Instead, they should reconstruct the sequence.
Perhaps:
14:00 was the preparation/start time entered in the BMR.
14:10 represented sample preparation rather than actual compression.
14:31 was the operator's entry through a particular access point.
14:37 was machine activation.
14:38 was the first automatically captured process event.
The apparent contradiction may disappear once the data-generating processes are understood.
Or it may reveal a genuine documentation problem.
That is precisely why investigation is required.
A batch has a data chain
A useful way to understand pharmaceutical data integrity is to think in terms of a data chain:
Material
↓
Activity
↓
Record
↓
Review
↓
Approval
↓
Decision
If something goes wrong at any point, the reliability of the final decision may be affected.
For example:
Raw material → Testing → Dispensing → Manufacturing → IPC → QC → QA → Release
Every arrow represents a potential information transfer.
Therefore, data integrity is not simply about individual records.
It is about the integrity of the entire chain.
Where can data-integrity risks hide?
1. Paper records
Potential risks include:
Backdating
Uncontrolled corrections
Missing entries
Unclear entries
Blank spaces
Uncontrolled forms
2. Laboratory systems
Potential risks include:
Shared accounts
Unauthorized reprocessing
Deleted data
Uncontrolled processing methods
Inadequate audit-trail review
3. Manufacturing systems
Potential risks include:
Changed process parameters
Unrecorded interventions
Incomplete electronic records
Inappropriate user access
4. ERP systems
Potential risks include:
Backdated transactions
Stock adjustments
Unauthorized changes
Incorrect master data
5. LIMS
Potential risks include:
Result modification
Sample manipulation
Inadequate approval controls
Inadequate audit-trail review
6. Access-control systems
Potential risks include:
Shared credentials
Incorrect user configuration
Time synchronization problems
Inadequate record retention
7. Backup systems
Potential risks include:
Failed backups
Incomplete backups
Inability to restore historical data
Inadequate retention
Why ALCOA+ is only the beginning
Most pharmaceutical professionals know the ALCOA+ principles.
Attributable
Legible
Contemporaneous
Original
Accurate
And additional principles such as:
Complete
Consistent
Enduring
Available
These principles remain fundamental.
But during an investigation, another question becomes extremely important:
Can the sequence of events be reconstructed?
For example:
Who → Did what → When → On which system → Using which data → What changed → Why → Who reviewed it → What decision followed?
That is where data governance, metadata and audit trails become particularly valuable.
What should a pharmaceutical company review during a batch investigation?
A practical investigation may need to consider multiple evidence sources.
Manufacturing
☐ BMR/BPR
☐ Equipment usage
☐ Cleaning records
☐ Calibration status
☐ Maintenance records
☐ IPC records
☐ Environmental records
Laboratory
☐ Raw data
☐ Chromatograms
☐ Sequences
☐ Audit trails
☐ Reprocessing
☐ Invalidated data
☐ Electronic signatures
Computerized Systems
☐ User access
☐ Privileged accounts
☐ Audit-trail status
☐ System clocks
☐ Backup availability
☐ Data restoration
Materials
☐ Receipt records
☐ Sampling records
☐ Dispensing records
☐ Material movement
☐ Reconciliation
Personnel
☐ Training
☐ Authorization
☐ Access records
☐ Interviews
Quality System
☐ Deviations
☐ OOS/OOT
☐ CAPA
☐ Change controls
☐ Previous investigations
The role of IT in modern GMP investigations
The traditional view was:
IT keeps the computers running.
Modern pharmaceutical manufacturing requires a much broader view.
IT/CSV teams may become critical participants in investigations involving:
LIMS
ERP/SAP
MES
CDS
HPLC/GC systems
Document management
Backup systems
User management
Audit trails
Network infrastructure
Time synchronization
Data archival
Disaster recovery
However, IT should not independently decide the quality significance of a data discrepancy.
That assessment normally requires appropriate involvement from the system owner, QA and relevant technical functions.
The strongest investigation is therefore cross-functional.
The role of QA
QA has a particularly important role because the question is ultimately not only:
“What happened?”
but also:
“What is the quality impact, and can the company demonstrate control?”
QA may need to evaluate:
Data reliability
Product impact
Patient risk
Scope
Historical batches
Related products
Similar systems
Deviations
CAPA
Regulatory reporting implications
Effectiveness of corrective actions
A recent FDA warning letter issued in July 2026 illustrates the seriousness with which data-integrity deficiencies can be treated. FDA called for a comprehensive investigation into the extent of inaccuracies across laboratories, manufacturing operations and systems, including omissions, alterations, deletions and non-contemporaneous record completion.
That is a useful reminder that a data-integrity investigation may need to go far beyond one document or one batch.
The most dangerous assumption in a pharmaceutical investigation
One of the most dangerous assumptions is:
“The BMR is complete, therefore the batch history is complete.”
That conclusion may be too simplistic.
The BMR is extremely important.
But depending on the manufacturing process and computerized systems involved, the overall evidence may also include:
BMR + BPR + Raw Data + Audit Trails + Equipment Records + Material Records + Environmental Data + Electronic Records + Quality Records
The goal is not to collect every piece of information in existence.
The goal is to identify the relevant evidence necessary to reconstruct and evaluate the event.
How pharmaceutical companies can strengthen their “digital shadow”
Companies can take several practical steps.
1. Map critical data flows
For each critical process, identify:
Where is data created?
Where is it processed?
Where is it stored?
Who can modify it?
Who reviews it?
How is it backed up?
How is it retrieved?
2. Control user access
Use unique user accounts wherever required.
Avoid uncontrolled shared accounts.
3. Protect audit trails
Audit trails should be appropriately configured, protected and reviewed according to system risk.
4. Synchronize system clocks
Time discrepancies can complicate investigations.
5. Protect original records
Do not treat a final PDF or printout as automatically equivalent to the complete original electronic record.
6. Validate computerized systems appropriately
Systems should remain in a validated state through their lifecycle.
7. Test backup and restoration
A backup that cannot be restored when required is not an adequate practical safeguard.
8. Train users
Training should address not only “how to operate the system” but also:
Why the data matter.
9. Conduct periodic data-integrity assessments
Do not wait for an inspection or major deviation.
The future of pharmaceutical inspections
The pharmaceutical industry is becoming increasingly digital.
Manufacturing facilities now use combinations of:
ERP
LIMS
MES
SCADA
BMS
CDS
Electronic Batch Records
Document Management Systems
Serialization
Access Control
Cloud/Backup Infrastructure
As these systems become interconnected, regulatory inspections are likely to increasingly involve questions about the relationship between systems and the integrity of the underlying data.
The question may no longer simply be:
“Show me the document.”
It may increasingly become:
“Show me the evidence that allows you to reconstruct what happened.”
The real lesson: Every batch has a story
Every pharmaceutical batch has a story.
The BMR tells part of that story.
The QC report tells another part.
The laboratory raw data tell another.
The equipment records tell another.
The audit trail tells another.
The material records tell another.
The environmental monitoring system may tell another.
The quality system tells another.
The real challenge is determining whether all these pieces form a consistent, reliable and scientifically defensible story.
That is the true importance of the pharmaceutical batch's digital shadow.
A batch may leave the factory as a physical product.
But it leaves behind a much larger trail of information.
And during a serious investigation, that information can become just as important as the product itself.
Frequently Asked Questions
What is a pharmaceutical batch investigation?
A pharmaceutical batch investigation is a structured examination of manufacturing, testing, documentation, computerized-system data and other relevant evidence to determine what happened and whether product quality, patient safety or data integrity may have been affected.
What is the digital shadow of a pharmaceutical batch?
“Digital shadow” is a descriptive term for the electronic and documentary information generated around a batch. It can include laboratory data, manufacturing data, audit trails, ERP transactions, equipment records, environmental data and other relevant information.
What is an audit trail in pharmaceutical manufacturing?
An audit trail is a record associated with actions affecting electronic data, such as creation, modification or deletion. It can help reconstruct the history of relevant electronic records.
Can HPLC audit trails be reviewed during a GMP investigation?
Yes. Where applicable, audit trails associated with chromatography data systems can help assess the history of analytical data, including processing activities and changes.
Does a discrepancy between two systems automatically mean data falsification?
No. A discrepancy should be investigated. Differences can arise from system design, timestamp configuration, workflow, manual documentation, synchronization issues or other legitimate causes.
Is data integrity only the responsibility of QC?
No. Data-integrity responsibilities can extend across QA, QC, Production, Engineering, Warehouse, IT, CSV, Regulatory Affairs and other functions depending on the data lifecycle.
Why are original electronic records important?
Original records and relevant metadata may contain information that cannot be reconstructed from a final report alone. They can be important for demonstrating how data were generated, processed, reviewed and approved.
Conclusion
The modern pharmaceutical factory is no longer just a collection of machines, laboratories and paper records.
It is a connected information environment.
A single pharmaceutical batch can generate thousands of pieces of information across multiple systems.
That creates a digital shadow.
Understanding that shadow is becoming increasingly important for:
QA professionals
QC professionals
Production teams
IT and CSV teams
Data-integrity professionals
Regulatory Affairs teams
Pharmaceutical management
and, ultimately, patient safety.
The most important question is therefore not simply:
“Is the batch record complete?”
It is:
“Can the evidence demonstrate what actually happened?”
That is the real test of data integrity.
Regulatory References
This article is intended for educational purposes. Pharmaceutical companies should always assess requirements against the regulations, guidance and approved procedures applicable to their operations.
Key reference documents include:
US FDA — Data Integrity and Compliance With Drug CGMP: Questions and Answers
WHO — Guideline on Data Integrity
CDSCO — Drugs Rules, 1945 / applicable Indian GMP requirements
Applicable company SOPs, data-integrity policies and computerized-system procedures.
No comments:
Post a Comment